Graybug Vision, Inc. (GRAY)
After hours:
| Previous Close | 2.2900 |
| Open | 2.2500 |
| Bid | 2.2700 x 800 |
| Ask | 2.3000 x 1100 |
| Day's Range | 2.2100 - 2.3200 |
| 52 Week Range | 2.2100 - 35.1800 |
| Volume | |
| Avg. Volume | 182,843 |
| Market Cap | 47.586M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Mar. 04, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.75 |
- GlobeNewswire
Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will be available on the conference website beginning at 10 a.
- GlobeNewswire
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments
BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the three and nine months ended September 30, 2021. Recent Corporate Developments Analysis of Data from Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD —
- GlobeNewswire
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced two clinical data presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting to be held on November 12-15, 2021 in New Orleans, Louisiana, as well as a company presentation at the Eyecelerator@AAO 2021 event on November 11, 2021:
